EVE Health Group (ASX: EVE) has appointed current chief operating officer Ben Rohr to the role of chief executive officer, effective immediately.
Mr Rohr has been instrumental in the company’s recent operational and commercial progress and brings with him a strong track record in execution, operational leadership, and capital management.
He has played a central role in the execution of EVE’s strategy including leading the integration of the $3 million Nextract acquisition and advancing the company’s pharmaceutical and commercial development programs.
He has also been closely involved in positioning core products Dyspro (to treat dysmenorrhoea and endometriosis) and Libbo (for erectile dysfunction) for regulatory progression and commercial rollout.
EVE’s current chief executive officer Damian Wood will move into the role of head of regulatory and medical affairs, with responsibility for regulatory strategy and clinical development across the company’s product pipeline.
Accelerated Commercialisation
Chair Rod Hannington said Mr Rohr’s appointment reflected the board’s focus on accelerating the commercialisation of EVE’s product portfolio and delivering disciplined growth across the business.
“Ben has demonstrated strong leadership and a clear ability to execute on the company’s strategy,” he said.
“His deep understanding of the business combined with his commercial focus positions him well to lead EVE through its next phase of growth.”
Mr Hannington said the revised corporate structure aligned EVE’s executive leadership with its strategic priorities, combining strong commercial execution with dedicated regulatory and clinical expertise.
Compound Reformulation Strategy
EVE is aiming to develop reformulated versions of established pharmaceutical compounds using novel delivery systems to improve bioavailability, onset of action, and patient convenience.
The strategy focuses on medicines approaching patent expiry where improved delivery formats may provide differentiated products that can be commercialised through licensing.
It also looks to leverage supply partnerships with pharmaceutical companies that have established regulatory capabilities, manufacturing infrastructure, and distribution networks.
The approach offers significant advantages over traditional drug discovery pathways using known safety profiles to reduce clinical development risk, targeting large markets with predictable demand, and employing shorter development timelines compared to novel drug development.
